ArriVent BioPharma, Inc. Common Stock (AVBP) — Long-term Investment Intensity
ArriVent BioPharma, Inc. Common Stock (AVBP) has a Long-term Investment Intensity of 1.6% as of September 2025. Long-term investments of $5.11 Million represent 1.6% of total assets of $326.56 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Explore ArriVent BioPharma, Inc. Common Stock (AVBP) cash conversion ratio to assess how effectively this company generates cash.
LT Investment Intensity
Long-term Investments
Total Assets
Country
ArriVent BioPharma, Inc. Common Stock Long-term Investment Intensity (2024–2024)
This chart shows how ArriVent BioPharma, Inc. Common Stock's Long-term Investment Intensity has evolved across 1 annual periods from 2024 to 2024. As of September 2025, the intensity stands at 1.6%, reflecting long-term investments of $5.11 Million against total assets of $326.56 Million USD. Explore AVBP cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for ArriVent BioPharma, Inc. Common Stock (2024–2024)
The table below presents the year-by-year Long-term Investment Intensity for ArriVent BioPharma, Inc. Common Stock from 2024 to 2024, covering 1 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see ArriVent BioPharma, Inc. Common Stock market capitalisation.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 17.3% | $47.68 Million | $274.94 Million | — |